American Society of Nephrology (ASN) October 1 - 2026 Supporting materials PRESENTATION: Sibeprenlimab in IgA Nephropathy: Phase 3 VISIONARY Kidney Outcomes Data ORAL PRESENTATION: Sibeprenlimab in IgA Nephropathy: Phase 3 VISIONARY Kidney Outcomes Data POSTER: Sibeprenlimab in IgA Nephropathy: Phase 3 VISIONARY Kidney Outcomes Data POSTER: A Registry-Based Study of Treatment Patterns and Outcomes in Patients With Focal Segmental Glomerulosclerosis in the United States PRESENTATION: Treatment Patterns, Response, and Relapse in Minimal Change Diseases: A US Registry Study POSTER: Adverse Clinical Outcomes and Economic Burden of Corticosteroid Use in Immunoglobulin A Nephropathy (IgAN): A US Real-World Study INFOGRAPHIC: Sibeprenlimab in IgA Nephropathy: Phase 3 VISIONARY 24-Month Analysis POSTER: Reduction of Kidney Manifestations With Tolvaptan Through 6 Years of the C-MAJOR Registry INFOGRAPHIC: IgA Nephropathy: The Evolving Treatment Paradigm and Selective APRIL Targeting
